Kyntra Bio targets FG-3246 median rPFS of 10 months or greater as it plans roxadustat Phase III start in Q4 2026 (NASDAQ:KYNB)
· seekingalpha.com
Kyntra Bio (KYNB) Q2 2026 earnings call: FG-3246/FG-3180 Phase II Q4 interim catalyst, roxadustat Phase III Q4’26 start, cash runway.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...